Driven by Innovation & Growth
Our mission is to promote innovation and growth through strengthened networks; advocacy; capital investment; talent attraction, development and retention; and advancing the next generation of leaders.
Virginia's Life Science Community By the Numbers
-
3,433 Companies
Life science companies in Virginia.
-
$8B Industry
Life Science contributes $8B to Virginia's economy.
-
30, 504 People
Employed by Life Science companies in Virginia.
-
$107,281 Average Wage
Average earnings of life science workers in Virginia.
-
1,197 Clinical trials
Biopharmaceutical industry-sponsored trials in Virginia per year.
News
03/17/2026
W&M Undergrads expand the chemical toolbox for cancer drugs
Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like …
03/17/2026
AgroSpheres and Wilbur-Ellis® Announce California Approval of FUN-THYME™
AgroSpheres and Wilbur-Ellis today announced that FUN-THYME, a broad-spectrum biofungicide co-developed by the two companies, has been approved for use in California. With demonstrated effectiveness on grapes, berries, apples, cherries, tomatoes and almonds, the new registration unlocks access for California growers. As the largest specialty crop producer in the United States, California is a defining …
03/16/2026
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75 …
Our Premium Partners
